Diaminopyrimidine derivatives and processes for the preparation thereof

A method for agonizing a 5-HT4 receptor, comprising administering an effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof:

• wherein,
• R1 is a phenyl group substituted with one or more substituents selected from the group consisting of amino, halogen, cyano, nitro, C1-5 alkyl (where the C1-5 alkyl is optionally substituted with halogen), C1-5 alkoxy, C1-5 alkylthio, and aminocarbonyl;
• or
• a heteroaryl group selected from the group consisting of quinolinyl, chromenonyl, benzofuranyl, indolyl, indolinyl, benzimidazolyl, and indazolyl, wherein the heteroaryl group may be optionally substituted with one or more C1-5 alkyl (where the C1-5 alkyl is optionally substituted with halogen),
• R2 is a nitrogen-containing cyclic group of the following Formula B (where * in Formula B represents the position attached to the compound of Formula 1),
• R3 is a C1-5 alkyl group,
• R4 is hydrogen;
• a C1-5 alkyl group optionally substituted with or a C1-5 alkoxycarbonyl group,
• R5 is hydrogen;
• a hydroxyl group;
• a benzyloxy group;
• a C1-5 alkyl group;
• or a group selected from the group consisting of the following Formulas E and I (where * in Formulas E and I represents the position attached to one of the compound of Formula B),
• R6 is hydrogen,
• X is —CH(R7)—;
• —N(R8)—;
• or —O—,
• R7 is hydrogen,
• R4 and R5 are optionally joined to each other to form a pentagonal or hexagonal ring,
• R8 is hydrogen;
• or a C1-5 alkyl group,
• R9 is a C1-10 alkyl group optionally substituted with hydroxy,
• R10 is hydrogen,
• R11 and R12 are, independently each other, hydrogen;
• or a C1-10 alkyl group optionally substituted with a substituent selected from the group consisting of C1-5 alkylthio, C3-10 cycloalkyl, phenyl (where the phenyl is optionally substituted with hydroxy), thiophenyl, pyrrolyl, and furanyl (where the furanyl is optionally substituted with mono- or di-C1-5 alkyl)),
• wherein the agonizing a 5-HT4 receptor effects to treat a dysfunction in gastrointestinal motility in a disease selected from the group consisting of gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, and diabetic gastric atony.